KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Gross Margin (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Gross Margin for 8 consecutive years, with 78.95% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 230.0% to 78.95% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 79.37% through Dec 2025, down 250.0% year-over-year, with the annual reading at 79.37% for FY2025, 250.0% down from the prior year.
  • Gross Margin hit 78.95% in Q4 2025 for Castle Biosciences, up from 77.48% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 86.73% in Q1 2021 to a low of 75.17% in Q4 2022.
  • Historically, Gross Margin has averaged 80.06% across 5 years, with a median of 80.9% in 2021.
  • Biggest five-year swings in Gross Margin: plummeted -886bps in 2022 and later surged 604bps in 2023.
  • Year by year, Gross Margin stood at 81.64% in 2021, then fell by -8bps to 75.17% in 2022, then rose by 8bps to 81.21% in 2023, then grew by 0bps to 81.25% in 2024, then decreased by -3bps to 78.95% in 2025.
  • Business Quant data shows Gross Margin for CSTL at 78.95% in Q4 2025, 77.48% in Q3 2025, and 79.55% in Q2 2025.